CS
RNAM

Candriam SCA’s Avidity Biosciences RNAM Stock Holding History

Candriam SCA’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-487,917
Closed -$21.3M – 712
2025
Q3 		$21.3M Buy
487,917
+45,144
+10% +$1.82M 0.11% 176
2025
Q2 		$12.6M Buy
442,773
+3,674
+0.8% +$110K 0.07% 213
2025
Q1 		$13M Buy
439,099
+78,389
+22% +$2.44M 0.08% 213
2024
Q4 		$10.5M Buy
360,710
+37,314
+12% +$1.56M 0.06% 252
2024
Q3 		$14.9M Buy
+323,396
New +$14M 0.09% 217
2024
Q1 		– Sell
-290,067
Closed -$2.63M – 725
2023
Q4 		$2.63M Buy
290,067
+120,000
+71% +$802K 0.02% 448
2023
Q3 		$1.09M Hold
170,067
– – 0.01% 541
2023
Q2 		$1.89M Hold
170,067
– – 0.01% 510
2023
Q1 		$2.4M Sell
170,067
-41,000
-19% -$902K 0.02% 533
2022
Q4 		$4.68M Hold
211,067
– – 0.03% 391
2022
Q3 		$3.45M Hold
211,067
– – 0.02% 462
2022
Q2 		$3.07M Buy
211,067
+51,079
+32% +$760K 0.03% 408
2022
Q1 		$2.96M Hold
159,988
– – 0.02% 463
2021
Q4 		$3.8M Buy
159,988
+1,400
+0.9% +$33.4K 0.02% 410
2021
Q3 		$3.91M Sell
158,588
-1,400
-0.9% -$30.4K 0.03% 444
2021
Q2 		$3.95M Buy
159,988
+140,491
+721% +$3.27M 0.03% 450
2021
Q1 		$478K Hold
19,497
– – ﹤0.01% 711
2020
Q4 		$498K Sell
19,497
-503
-3% -$14.7K ﹤0.01% 724
2020
Q3 		$563K Hold
20,000
– – 0.01% 699
2020
Q2 		$565K Buy
+20,000
New +$577K 0.01% 694

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Candriam SCA's RNAM Position: Q4 2025 in Review

Candriam SCA sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 487,917 shares — an estimated $21.3M sold.

Candriam SCA first reported a position in RNAM in Q2 2020 and held it in 20 quarters. The position peaked at $21.3M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Candriam SCA reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Candriam SCA sold 487,917 Avidity Biosciences shares in Q4 2025, an estimated $21.3M.
  • Candriam SCA first reported a position in Avidity Biosciences in Q2 2020 and held it in 20 quarters.
  • Candriam SCA's Avidity Biosciences position peaked at $21.3M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Candriam SCA's 13F filing for Q4 2025, filed 13 Feb 2026.